Evidence map›Paper›PMID 38233377›Full record

ArticleCell death & disease2024

c-Fos regulated by TMPO/ERK axis promotes 5-FU resistance via inducing NANOG transcription in colon cancer.

Yanping Gui, Xiaoping Qian, Youxiang Ding, Qianqian Chen, Fangyu Ye, Yuting Ye, Yingjian Hou, Jun Yu, Li Zhao

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
9.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. FRA1 (Frontiers in cell and developmental biology · 2025
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Yanping Gui *Public Experimental Platform, China Pharmaceutical University, Nanjing, 211198, China.
Xiaoping Qian *Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, 215153, China.
Youxiang Ding *Department of Pathology, Nanjing Drum Tower Hospital, Affiliated to Medical College of Nanjing University, Nanjing, 210008, China.
Qianqian ChenPublic Experimental Platform, China Pharmaceutical University, Nanjing, 211198, China.
Fangyu YePublic Experimental Platform, China Pharmaceutical University, Nanjing, 211198, China.
Yuting YePublic Experimental Platform, China Pharmaceutical University, Nanjing, 211198, China.
Yingjian HouPublic Experimental Platform, China Pharmaceutical University, Nanjing, 211198, China.
Jun YuJiangsu Cancer Hospital, Nanjing, 210009, China.
Li ZhaoPublic Experimental Platform, China Pharmaceutical University, Nanjing, 211198, China. zhaoli@cpu.edu.cn.ORCID 0000-0003-1576-8787
China Pharmaceutical University · CNJiangsu Cancer Hospital · CNNanjing Drum Tower Hospital · CNSuzhou Municipal Hospital · CN

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82273962
6 · The paper itself

Abstract

Acquired drug resistance is one of the most common limitations for the clinical response of colon cancer to 5-Fluorouracil (5-FU)-based chemotherapy. The relevant molecular mechanisms might be diversity, but still not be elucidated clearly. In this study, we aimed to investigate the potential mechanisms of c-Fos, a subfamily of activator protein-1, in 5-FU chemoresistance. We determined that phosphorylated c-Fos promoted colon cancer cells resistance to 5-FU by facilitating the cancer stemness. Mechanically, 5-FU treatment induced autolysosome-dependent degradation of TMPO, which subsequently triggered ERK-mediated phosphorylation of c-Fos. Additionally, c-Fos was found to bind to the promoter of NANOG and phosphorylation of c-Fos at Ser 374 was required for its regulation of NANOG expression. NANOG ablation impaired c-Fos/p-c-Fos induced 5-FU resistance and stemness. Taken together, these findings revealed that TMPO-mediated phosphorylation of c-Fos conferred 5-FU resistance by regulating NANOG expression and promoting cell stemness in colon cancer cells. c-Fos could be as a therapeutic target for colon cancer.

Indexed as

Colonic NeoplasmsCyclic N-OxidesThymopoietinsCell Line, TumorDrug Resistance, NeoplasmFluorouracilGene Expression Regulation, NeoplasticHumansNanog Homeobox ProteinNuclear ProteinsProto-Oncogene Proteins c-fos3,3,5,5-tetramethyl-1-pyrroline N-oxideCyclic N-OxidesFluorouracilNanog Homeobox ProteinNANOG protein, humanNuclear ProteinsProto-Oncogene Proteins c-fosThymopoietinsTMPO protein, human

Identifiers

PMID38233377
PMCPMC10794174
OpenAlexW4390947458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.